Overview

Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib

Status:
Recruiting

Trial end date:
2025-11-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and efficacy of giving atezolizumab combined with bevacizumab in patients with stage 4 epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) whose cancer has gotten worse while receiving osimertinib.

Phase:

Phase 2

Details

Lead Sponsor:

Duke University

Treatments:

Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Osimertinib